Skip to main content
OpenTrials
Completed

NCT Number: NCT04429815

Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19

Several studies have shown that smokers have a higher risk of developing a severe form of COVID-19 once a person has been infected. This is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. In contrast, recent data indicate that smokers are proportionally less infected with the COVID-19 virus since all available cohort data from around the world show a very low rate of smokers among COVID-19 infected subjects. The mechanisms at the origin of this protective effect are not known. All of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the COVID-19 virus.

The objectives are :

* To show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with COVID-19 than non-smokers. * To show that active smokers are less infected with COVID-19 than non-smokers. * To compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU Nancy

Vandœuvre-lès-Nancy, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years old
  • Subject who will require a serological test for COVID-19 virus as part of standard of care.
  • Group 1: Active smoker since October 2019
  • Group 2: Smoker undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019
  • Group 3: Non-smoker

Exclusion criteria

  • Inpatient subject
  • Subjects with a chronic serious pathology modifying the risk of exposure to COVID-19

Treatment and study plan

Serological test for COVID-19.

Diagnostic Test

Serological test for COVID-19 performed as part of standard of care.

Primary outcomes

  1. Percentage of patients with a positive serological test for COVID-19.

    Time frame: 1 day

    Percentage of patients with a positive serological test for COVID-19.

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: MAGIC

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jun 12, 2020
Registry last updated
Aug 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.